{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:24:29Z","timestamp":1791051869775,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer and cancer therapies are a major factor risk for osteoporosis due to bone loss and deterioration of bone microarchitecture. Both factors contribute to a decrease in bone strength and, consequently, increased bone fragility and risk of fracture. Cancer-associated bone loss is a multifactorial process, and optimal interdisciplinary management of skeletal health, accurate assessment of bone density, and early diagnosis are essential when making decisions aimed at reducing bone loss and fracture risk in patients who have received or are receiving treatment for cancer. In this document, a multidisciplinary group of experts collected the latest evidence on the pathophysiology of osteoporosis and its prevention, diagnosis, and treatment with the support of the Spanish scientific society SEOM. The aim was to provide an up-to-date and in-depth view of osteoporotic risk and its consequences, and to present a series of recommendations aimed at optimizing the management of bone health in the context of cancer.<\/jats:p>","DOI":"10.1007\/s12094-022-02872-1","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T12:25:27Z","timestamp":1656764727000},"page":"2090-2106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Bone loss induced by cancer treatments in breast and prostate cancer patients"],"prefix":"10.1007","volume":"24","author":[{"given":"Santos","family":"Casta\u00f1eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Mart\u00ednez-D\u00edaz-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Nogu\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ojeda Thies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Torregrosa Suau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-5290","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Rodr\u00edguez-Lescure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"issue":"6","key":"2872_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","volume":"94","author":"WA Peck","year":"1993","unstructured":"Peck WA. Consensus development conference\u202f: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646\u201350.","journal-title":"Am J Med"},{"issue":"9","key":"2872_CR2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2015.09.003","volume":"41","author":"S D'Oronzo","year":"2015","unstructured":"D\u2019Oronzo S, Stucci S, Tucci M, Silvestris F. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev. 2015;41(9):798\u2013808.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2872_CR3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12094-016-1529-6","volume":"19","author":"A Carmona-Bayonas","year":"2017","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Casta\u00f1\u00f3n E, Ramchandani-Vaswani A, S\u00e1nchez-Bayona R, Custodio A, Calvo-Temprano D, Virizuela JA. Chronic opioid therapy in long-term cancer survivors. Clin Transl Oncol. 2017;19(2):236\u201350.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"2872_CR4","first-page":"1665","volume":"28","author":"Y Imanishi","year":"2018","unstructured":"Imanishi Y. Secondary osteoporosis Cancer treatment-induced bone loss. Clin Calcium. 2018;28(12):1665\u201370.","journal-title":"Clin Calcium"},{"issue":"4","key":"2872_CR5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apmr.2010.10.039","volume":"92","author":"KM Winters-Stone","year":"2011","unstructured":"Winters-Stone KM, Torgrimson B, Horak F, Eisner A, Nail L, Leo MC, Chui S, Luoh SW. Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach. Arch Phys Med Rehabil. 2011;92(4):646\u201352.","journal-title":"Arch Phys Med Rehabil"},{"issue":"12","key":"2872_CR6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B, Ten,. year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12(12):989\u201395.","journal-title":"Osteoporos Int"},{"issue":"10169","key":"2872_CR7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364\u201376.","journal-title":"Lancet"},{"issue":"12","key":"2872_CR8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","volume":"332","author":"SR Cummings","year":"1995","unstructured":"Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332(12):767\u201373.","journal-title":"N Engl J Med"},{"issue":"23","key":"2872_CR9","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1001\/jama.298.23.2761","volume":"298","author":"JA Cauley","year":"2007","unstructured":"Cauley JA, Hochberg MC, Lui LY, Palermo L, Ensrud KE, Hillier TA, Nevitt MC, Cummings SR. Long-term risk of incident vertebral fractures. JAMA. 2007;298(23):2761\u20137.","journal-title":"JAMA"},{"issue":"4","key":"2872_CR10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.297.4.387","volume":"297","author":"JR Center","year":"2007","unstructured":"Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297(4):387\u201394.","journal-title":"JAMA"},{"issue":"3","key":"2872_CR11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jbmr.1476","volume":"27","author":"S Gehlbach","year":"2012","unstructured":"Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, Chapurlat RD, Compston JE, Cooper C, Diez-Perez A, Greenspan SL, LaCroix AZ, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Sambrook PN, Silverman S, Siris ES, Watts NB, Lindsay R. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012;27(3):645\u201353.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2872_CR12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375\u201382.","journal-title":"Bone"},{"issue":"6","key":"2872_CR13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581\u20139.","journal-title":"Osteoporos Int"},{"issue":"1","key":"2872_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","volume":"68","author":"M Rossini","year":"2016","unstructured":"Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, Isaia GC. Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo. 2016;68(1):1\u201339.","journal-title":"Reumatismo"},{"issue":"6","key":"2872_CR15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.med.0000436195.10599.dd","volume":"20","author":"AM Cheung","year":"2013","unstructured":"Cheung AM, Heisey R, Srighanthan J. Breast cancer and osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):532\u20138.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2872_CR16","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1757","volume":"9","author":"PE Goss","year":"2007","unstructured":"Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res. 2007;9(4):R52.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2872_CR17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/ar2791","volume":"11","author":"JA Roman-Blas","year":"2009","unstructured":"Roman-Blas JA, Castaneda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009;11(5):241.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2872_CR18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00223-017-0369-x","volume":"102","author":"C Handforth","year":"2018","unstructured":"Handforth C, D\u2019Oronzo S, Coleman R, Brown J. Cancer Treatment and Bone Health. Calcif Tissue Int. 2018;102(2):251\u201364.","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2872_CR19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, Hofbauer LC. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018;6(11):901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2872_CR20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","volume":"38","author":"P Hadji","year":"2012","unstructured":"Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A, Aapro MS. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev. 2012;38(6):798\u2013806.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2872_CR21","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/annonc\/mdr448","volume":"23","author":"K Zaman","year":"2012","unstructured":"Zaman K, Thurlimann B, Huober J, Schonenberger A, Pagani O, Luthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S, Swiss Group for Clinical Cancer. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1\u201398 study (SAKK 21\/07). Ann Oncol. 2012;23(6):1474\u201381.","journal-title":"Ann Oncol"},{"issue":"1\u20132","key":"2872_CR22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mce.2009.07.001","volume":"310","author":"KM Nicks","year":"2009","unstructured":"Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D. Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones. Activin Inhibin Mol Cell Endocrinol. 2009;310(1\u20132):11\u201320.","journal-title":"Activin Inhibin Mol Cell Endocrinol"},{"issue":"3","key":"2872_CR23","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/EJE-15-0118","volume":"173","author":"F Mirza","year":"2015","unstructured":"Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131\u201351.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2872_CR24","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"31","key":"2872_CR25","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897\u2013903.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2872_CR26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154\u201364.","journal-title":"N Engl J Med"},{"issue":"3","key":"2872_CR27","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","volume":"69","author":"J Morote","year":"2007","unstructured":"Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69(3):500\u20134.","journal-title":"Urology"},{"key":"2872_CR28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/EDBK_201411","volume":"38","author":"T Bao","year":"2018","unstructured":"Bao T, Peppone LJ, Robinson P. Addressing the unintentional consequences of cancer therapy with novel integrative therapeutics. Am Soc Clin Oncol Educ Book. 2018;38:822\u20138.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"2872_CR29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1464-410X.2008.07539.x","volume":"102","author":"DA Galvao","year":"2008","unstructured":"Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102(1):44\u20137.","journal-title":"BJU Int"},{"issue":"4","key":"2872_CR30","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.urology.2010.11.024","volume":"77","author":"K Bylow","year":"2011","unstructured":"Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W. Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology. 2011;77(4):934\u201340.","journal-title":"Urology"},{"issue":"5","key":"2872_CR31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaci.2013.08.040","volume":"132","author":"B Buehring","year":"2013","unstructured":"Buehring B, Viswanathan R, Binkley N, Busse W. Glucocorticoid-induced osteoporosis: an update on effects and management. J Allergy Clin Immunol. 2013;132(5):1019\u201330.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2872_CR32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11914-012-0131-2","volume":"11","author":"SP Tuck","year":"2013","unstructured":"Tuck SP, Hanusch B, Walker J, Datta HK. Prostate cancer and osteoporosis. Curr Osteoporos Rep. 2013;11(1):11\u201320.","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"2872_CR33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0090-4295(94)90183-X","volume":"43","author":"M Iwamura","year":"1994","unstructured":"Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology. 1994;43(5):675\u20139.","journal-title":"Urology"},{"issue":"4","key":"2872_CR34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s002239900240","volume":"60","author":"S Castaneda","year":"1997","unstructured":"Castaneda S, Carmona L, Carvajal I, Arranz R, Diaz A, Garcia-Vadillo A. Reduction of bone mass in women after bone marrow transplantation. Calcif Tissue Int. 1997;60(4):343\u20137.","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"2872_CR35","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00198-018-4669-4","volume":"29","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Body JJ, Brandi ML, Broady R, Cannata-Andia J, Cannata-Ortiz MJ, El Maghraoui A, Guglielmi G, Hadji P, Pierroz DD, de Villiers TJ, Rizzoli R, Ebeling PR, International Osteoporosis Foundation Committee of Scientific Advisors Working Group on, C. Bone management in hematologic stem cell transplant recipients. Osteoporos Int. 2018;29(12):2597\u2013610.","journal-title":"Osteoporos Int"},{"issue":"8","key":"2872_CR36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.bbmt.2010.02.017","volume":"16","author":"S Yao","year":"2010","unstructured":"Yao S, Smiley SL, West K, Lamonica D, Battiwalla M, McCarthy PL Jr, Hahn T. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16(8):1130\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2872_CR37","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1359\/jbmr.1999.14.3.342","volume":"14","author":"PR Ebeling","year":"1999","unstructured":"Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res. 1999;14(3):342\u201350.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2872_CR38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137\u201341.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2872_CR39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, Group, I.-I.B.M.S.W. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391\u2013420.","journal-title":"Osteoporos Int"},{"issue":"1","key":"2872_CR40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-017-0097-4","volume":"5","author":"T-R Kuo","year":"2017","unstructured":"Kuo T-R, Chen C-H. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomarker Res. 2017;5(1):18.","journal-title":"Biomarker Res"},{"key":"2872_CR41","doi-asserted-by":"crossref","unstructured":"Borgen TT, Solberg LB, Lauritzen T, Apalset EM, Bj\u00f8rnerem \u00c5, Eriksen EF. Target values and daytime variation of bone turnover markers in monitoring osteoporosis treatment after fractures. JBMR Plus, 2022;n\/a(n\/a): e10633.","DOI":"10.1002\/jbm4.10633"},{"issue":"2","key":"2872_CR42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jbmr.4178","volume":"36","author":"R Eastell","year":"2021","unstructured":"Eastell R, Black DM, Lui L-Y, Chines A, Marin F, Khosla S, de Papp AE, Cauley JA, Mitlak B, McCulloch CE, Vittinghoff E, Bauer DC, for the Foundation for the National Institutes of Health Bone Quality, P. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. J Bone Miner Res. 2021;36(2):236\u201343.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2872_CR43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3949\/ccjm.75.10.739","volume":"75","author":"FR Singer","year":"2008","unstructured":"Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med. 2008;75(10):739\u201350.","journal-title":"Cleve Clin J Med"},{"issue":"8","key":"2872_CR44","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/nu10081103","volume":"10","author":"D Agostini","year":"2018","unstructured":"Agostini D, Zeppa Donati S, Lucertini F, Annibalini G, Gervasi M, Ferri Marini C, Piccoli G, Stocchi V, Barbieri E, Sestili P. Muscle and bone health in postmenopausal women: role of protein and vitamin d supplementation combined with exercise training. Nutrients. 2018;10(8):1103.","journal-title":"Nutrients"},{"issue":"6","key":"2872_CR45","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2105\/AJPH.90.6.947","volume":"90","author":"N de Jong","year":"2000","unstructured":"de Jong N, Chin APMJ, de Groot LC, Hiddink GJ, van Staveren WA. Dietary supplements and physical exercise affecting bone and body composition in frail elderly persons. Am J Public Health. 2000;90(6):947\u201354.","journal-title":"Am J Public Health"},{"issue":"2","key":"2872_CR46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1359\/jbmr.2003.18.2.343","volume":"18","author":"HA Bischoff","year":"2003","unstructured":"Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C, Nebiker M, Theiler R, Pfeifer M, Begerow B, Lew RA, Conzelmann M. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003;18(2):343\u201351.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2872_CR47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jbmr.3886","volume":"35","author":"M Pineda-Moncusi","year":"2020","unstructured":"Pineda-Moncusi M, Garcia-Giralt N, Diez-Perez A, Servitja S, Tusquets I, Prieto-Alhambra D, Nogues X. Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates. J Bone Miner Res. 2020;35(2):291\u20137.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2872_CR48","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10549-010-1075-9","volume":"125","author":"D Prieto-Alhambra","year":"2011","unstructured":"Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-Garc\u00eda M, Diez-Perez A, Albanell J, Tusquets I, Nogues X. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat. 2011;125(3):869\u201378.","journal-title":"Breast Cancer Res Treat"},{"key":"2872_CR49","unstructured":"National Comprehensive Cancer Network. Guidelines for treatment of cancer by site: breast cancer v5; 2021. https:\/\/www.nccn.org\/guidelines\/category_1#site."},{"key":"2872_CR50","unstructured":"National Comprehensive Cancer Network. Guidelines for treatment of cancer by site: Prostate cancer v2.2021. https:\/\/www.nccn.org\/guidelines\/category_1#site."},{"issue":"4","key":"2872_CR51","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","volume":"99","author":"J Planas","year":"2007","unstructured":"Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventos CX. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 2007;99(4):812\u20135.","journal-title":"BJU Int"},{"issue":"10","key":"2872_CR52","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3390\/nu6104491","volume":"6","author":"A Dueregger","year":"2014","unstructured":"Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H, Eder IE. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients. 2014;6(10):4491\u2013519.","journal-title":"Nutrients"},{"issue":"2","key":"2872_CR53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s13679-021-00433-1","volume":"10","author":"I Karampela","year":"2021","unstructured":"Karampela I, Sakelliou A, Vallianou N, Christodoulatos GS, Magkos F, Dalamaga M. Vitamin D and obesity: current evidence and controversies. Curr Obes Rep. 2021;10(2):162\u201380.","journal-title":"Curr Obes Rep"},{"key":"2872_CR54","doi-asserted-by":"crossref","unstructured":"Abdullah Thani NSI, Khairudin R, Ho JJ, Muhamad NA, Ismail H. Vitamin D supplementation for overweight or obese adults. Cochrane Database Syst. Rev. 2019(5): CD011629.","DOI":"10.1002\/14651858.CD011629.pub2"},{"key":"2872_CR55","doi-asserted-by":"crossref","unstructured":"Migliaccio S, Di Nisio A, Mele C, Scappaticcio L, Savastano S, Colao A. Obesity programs of nutrition, E.R., and assessment, G., obesity and hypovitaminosis D: causality or casualty? International journal of obesity supplements, 2019. 9(1): 20\u201331.","DOI":"10.1038\/s41367-019-0010-8"},{"key":"2872_CR56","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1007\/s12094-020-02312-y","volume":"22","author":"M Pollan","year":"2020","unstructured":"Pollan M, Casla-Barrio S, Alfaro J, Esteban C, Segui-Palmer MA, Lucia A, Martin M. Exercise and cancer: a position statement from the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020;22:1710.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"2872_CR57","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00198-017-4237-3","volume":"29","author":"J Dalla Via","year":"2018","unstructured":"Dalla Via J, Daly RM, Fraser SF. The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis. Osteoporos Int. 2018;29(2):287\u2013303.","journal-title":"Osteoporos Int"},{"issue":"5","key":"2872_CR58","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.euo.2018.11.001","volume":"2","author":"JS Joseph","year":"2019","unstructured":"Joseph JS, Lam V, Patel MI. Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2019;2(5):551\u201361.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"2872_CR59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11764-017-0622-3","volume":"11","author":"CP Fornusek","year":"2017","unstructured":"Fornusek CP, Kilbreath SL. Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses. J Cancer Surviv. 2017;11(5):525\u201341.","journal-title":"J Cancer Surviv"},{"issue":"3","key":"2872_CR60","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12094-014-1184-8","volume":"17","author":"S Casla","year":"2015","unstructured":"Casla S, Hojman P, M\u00e1rquez-Rodas I, L\u00f3pez-Tarruella S, Jerez Y, Barakat R, Mart\u00edn M. Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. Clin Transl Oncol. 2015;17(3):180\u201396.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"2872_CR61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00198-017-4339-y","volume":"29","author":"A Varahra","year":"2018","unstructured":"Varahra A, Rodrigues IB, MacDermid JC, Bryant D, Birmingham T. Exercise to improve functional outcomes in persons with osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 2018;29(2):265\u201386.","journal-title":"Osteoporos Int"},{"issue":"1","key":"2872_CR62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.25082\/CCR.2019.01.002","volume":"1","author":"SS Coughlin","year":"2019","unstructured":"Coughlin SS, Caplan L, Stone R, Stewart J. A review of home-based physical activity interventions for breast cancer survivors. Curr Cancer Rep. 2019;1(1):6\u201312.","journal-title":"Curr Cancer Rep"},{"key":"2872_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/pzab288","author":"B Bressi","year":"2020","unstructured":"Bressi B, Cagliari M, Contesini M, Mazzini E, Bergamaschi FAM, Moscato A, Bassi MC, Costi S. Physical exercise for bone health in men with prostate cancer receiving androgen deprivation therapy: a systematic review. Support Care Cancer. 2020. https:\/\/doi.org\/10.1093\/ptj\/pzab288.","journal-title":"Support Care Cancer"},{"issue":"27","key":"2872_CR64","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007368","volume":"96","author":"G Yunfeng","year":"2017","unstructured":"Yunfeng G, Weiyang H, Xueyang H, Yilong H, Xin G. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis. Medicine (Baltimore). 2017;96(27): e7368.","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 2","key":"2872_CR65","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1017\/S0007114512001638","volume":"107","author":"TS Orchard","year":"2012","unstructured":"Orchard TS, Pan X, Cheek F, Ing SW, Jackson RD. A systematic review of omega-3 fatty acids and osteoporosis. Br J Nutr. 2012;107(Suppl 2):S253\u201360.","journal-title":"Br J Nutr"},{"key":"2872_CR66","doi-asserted-by":"crossref","unstructured":"O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev, 2017. 10: CD003474.","DOI":"10.1002\/14651858.CD003474.pub4"},{"issue":"7","key":"2872_CR67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25(7):829\u201336.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2872_CR68","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118(5):1192\u2013201.","journal-title":"Cancer"},{"issue":"11","key":"2872_CR69","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","volume":"21","author":"H Eidtmann","year":"2010","unstructured":"Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21(11):2188\u201394.","journal-title":"Ann Oncol"},{"issue":"3","key":"2872_CR70","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","volume":"117","author":"SL Hines","year":"2009","unstructured":"Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009;117(3):603\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"2872_CR71","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/cncr.29327","volume":"121","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Sloan JA, Liu H, Kearns AE, Hines SL, Puttabasavaiah S, Dakhil SR, Lafky JM, Perez EA, Loprinzi CL. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer. 2015;121(15):2537\u201343.","journal-title":"Cancer"},{"issue":"6","key":"2872_CR72","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","volume":"28","author":"C Van Poznak","year":"2010","unstructured":"Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28(6):967\u201375.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2872_CR73","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00198-015-3100-7","volume":"26","author":"SL Greenspan","year":"2015","unstructured":"Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporos Int. 2015;26(6):1857\u201364.","journal-title":"Osteoporos Int"},{"key":"2872_CR74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bone.2016.03.010","volume":"90","author":"C Prasad","year":"2016","unstructured":"Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial. Bone. 2016;90:123\u20136.","journal-title":"Bone"},{"issue":"5","key":"2872_CR75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/M16-2577","volume":"167","author":"SMH Alibhai","year":"2017","unstructured":"Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Tomlinson GA, Winquist E. Bone Health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2017;167(5):341\u201350.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2872_CR76","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.7314\/APJCP.2013.14.5.3337","volume":"14","author":"H Ding","year":"2013","unstructured":"Ding H, Yang L, Du W, Teng Y, Fu SJ, Tao Y, Lu JZ, Wang ZP. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2013;14(5):3337\u201343.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"15","key":"2872_CR77","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","volume":"38","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, Kungel TM, Nissenberg MG, Michalski JM. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care ontario guideline. J Clin Oncol. 2020;38(15):1736\u201343.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2872_CR78","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2872_CR79","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365.","journal-title":"N Engl J Med"},{"key":"2872_CR80","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fcell.2020.00325","volume":"8","author":"N Zhang","year":"2020","unstructured":"Zhang N, Zhang Z-K, Yu Y, Zhuo Z, Zhang G, Zhang B-T. Pros and Cons of Denosumab treatment for osteoporosis and implication for RANKL aptamer therapy. Front Cell Develop Biol. 2020;8:325.","journal-title":"Front Cell Develop Biol"},{"issue":"30","key":"2872_CR81","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875\u201382.","journal-title":"J Clin Oncol"},{"key":"2872_CR82","doi-asserted-by":"crossref","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R., Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R., Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF, Austrian B, Colorectal Cancer Study G. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, 2015:386(9992); p. 433\u201343.","DOI":"10.1016\/S0140-6736(15)60995-3"},{"key":"2872_CR83","doi-asserted-by":"crossref","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HPCSG. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009. 361(8): 745\u201355.","DOI":"10.1056\/NEJMoa0809003"},{"issue":"31","key":"2872_CR84","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916\u201346.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2872_CR85","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465\u201373.","journal-title":"Osteoporos Int"},{"issue":"19","key":"2872_CR86","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434\u201341.","journal-title":"N Engl J Med"},{"key":"2872_CR87","doi-asserted-by":"crossref","unstructured":"Riancho JA, Peris P, Gonz\u00e1lez-Mac\u00edas J, P\u00e9rez-Castrill\u00f3n JL, Gu\u00edas de Pr\u00e1ctica Cl\u00ednica en la Osteoporosis Posmenop\u00e1usica, Glicocorticoidea y del var\u00f3n (actualizaci\u00f3n 2021). Sociedad Espa\u00f1ola de Investigaci\u00f3n \u00d3sea y del Metabolismo Mineral (SEIOMM). Rev Clin Esp, 2022 (in press).","DOI":"10.1016\/j.rce.2021.12.007"},{"issue":"10102","key":"2872_CR88","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585\u201394.","journal-title":"Lancet"},{"issue":"8","key":"2872_CR89","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. Effects of 24 months of treatment with romosozumab followed by 12 Months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397\u2013406.","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2872_CR90","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"2872_CR91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, Investigators I-I. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67\u201375.","journal-title":"Lancet Oncol"},{"key":"2872_CR92","doi-asserted-by":"crossref","unstructured":"Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int, 1995; 56(3): 181\u20135.","DOI":"10.1007\/BF00298606"},{"key":"2872_CR93","doi-asserted-by":"crossref","unstructured":"Carstens JH, Feinblatt JD. Future horizons for calcitonin: a U.S. perspective. Calcif Tissue Int, 1991; 49 Suppl 2: p. S2\u20136.","DOI":"10.1007\/BF02561368"},{"issue":"6697","key":"2872_CR94","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.299.6697.477","volume":"299","author":"K Overgaard","year":"1989","unstructured":"Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ. 1989;299(6697):477\u20139.","journal-title":"BMJ"},{"issue":"1","key":"2872_CR95","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body J-J, Gonzalez Rodriguez E, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2021;106(1):264\u201381.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2872_CR96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12916-020-01514-z","volume":"18","author":"AC Meyer","year":"2020","unstructured":"Meyer AC, Drefahl S, Ahlbom A, Lambe M, Modig K. Trends in life expectancy: did the gap between the healthy and the ill widen or close? BMC Med. 2020;18(1):41.","journal-title":"BMC Med"},{"key":"2872_CR97","doi-asserted-by":"crossref","unstructured":"Buckley RE, Moran CG, Apivatthakakul T, AO Principles of Fracture Management: Vol. 1: Principles, Vol 2: Specific Fractures. 2017: Thieme Medical Publishers","DOI":"10.1055\/b-0038-160811"},{"issue":"Suppl 2","key":"2872_CR98","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1007\/s00198-004-1763-6","volume":"16","author":"R Curtis","year":"2005","unstructured":"Curtis R, Goldhahn J, Schwyn R, Regazzoni P, Suhm N. Fixation principles in metaphyseal bone\u2013a patent based review. Osteoporos Int. 2005;16(Suppl 2):S54-64.","journal-title":"Osteoporos Int"},{"issue":"10","key":"2872_CR99","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5435\/JAAOS-D-17-00749","volume":"27","author":"CN Johnson","year":"2019","unstructured":"Johnson CN, Gurich RW Jr, Pavey GJ, Thompson MJ. Contemporary management of appendicular skeletal metastasis by primary tumor type. J Am Acad Orthop Surg. 2019;27(10):345\u201355.","journal-title":"J Am Acad Orthop Surg"},{"issue":"5","key":"2872_CR100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1302\/2058-5241.1.000008","volume":"1","author":"JJ Willeumier","year":"2016","unstructured":"Willeumier JJ, van der Linden YM, van de Sande MAJ, Dijkstra PDS. Treatment of pathological fractures of the long bones. EFORT Open Rev. 2016;1(5):136\u201345.","journal-title":"EFORT Open Rev"},{"issue":"8","key":"2872_CR101","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/medicina56080397","volume":"56","author":"L Rodrigues","year":"2020","unstructured":"Rodrigues L, Cornelis FH, Chevret S. Hip fracture prevention in osteoporotic elderly and cancer patients: an on-line french survey evaluating current needs. Medicina (Kaunas). 2020;56(8):397.","journal-title":"Medicina (Kaunas)"},{"key":"2872_CR102","doi-asserted-by":"crossref","unstructured":"Giannini S, Chiarello E, Mazzotti A, Tedesco G, Faldini C. Surgical prevention of femoral neck fractures in elderly osteoporotic patients: a randomised controlled study on the prevention nail system device. Hip Int, 2018. 28(2_suppl): 78\u201383.","DOI":"10.1177\/1120700018813207"},{"issue":"1","key":"2872_CR103","first-page":"42","volume":"13","author":"E Chiarello","year":"2016","unstructured":"Chiarello E, Tedesco G, Cadossi M, Capra P, Terrando S, Miti A, Giannini S. Surgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature review. Clin Cases Miner Bone Metab. 2016;13(1):42\u20135.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"3","key":"2872_CR104","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/SPC.0b013e328349652d","volume":"5","author":"K Aghayev","year":"2011","unstructured":"Aghayev K, Papanastassiou ID, Vrionis F. Role of vertebral augmentation procedures in the management of vertebral compression fractures in cancer patients. Curr Opin Support Palliat Care. 2011;5(3):222\u20136.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"9","key":"2872_CR105","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00264-015-3047-5","volume":"40","author":"M Ollivier","year":"2016","unstructured":"Ollivier M, Turati M, Munier M, Lunebourg A, Argenson JN, Parratte S. Balloon tibioplasty for reduction of depressed tibial plateau fractures: Preliminary radiographic and clinical results. Int Orthop. 2016;40(9):1961\u20136.","journal-title":"Int Orthop"},{"issue":"4","key":"2872_CR106","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jvir.2019.11.029","volume":"31","author":"FY Lee","year":"2020","unstructured":"Lee FY, Latich I, Toombs C, Mungur A, Conway D, Alder K, Ibe I, Lindskog D, Friedlaender G. Minimally invasive image-guided ablation, osteoplasty, reinforcement, and internal fixation (AORIF) for osteolytic lesions in the pelvis and periarticular regions of weight-bearing bones. J Vasc Interv Radiol. 2020;31(4):649-658e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"2872_CR107","doi-asserted-by":"crossref","first-page":"936","DOI":"10.2106\/JBJS.17.01222","volume":"100","author":"C Kammerlander","year":"2018","unstructured":"Kammerlander C, Pfeufer D, Lisitano LA, Mehaffey S, Bocker W, Neuerburg C. Inability of older adult patients with hip fracture to maintain postoperative weight-bearing restrictions. J Bone Joint Surg Am. 2018;100(11):936\u201341.","journal-title":"J Bone Joint Surg Am"},{"issue":"10","key":"2872_CR108","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1302\/0301-620X.100B10.BJJ-2018-0489.R1","volume":"100B","author":"TD Ottesen","year":"2018","unstructured":"Ottesen TD, McLynn RP, Galivanche AR, Bagi PS, Zogg CK, Rubin LE, Grauer JN. Increased complications in geriatric patients with a fracture of the hip whose postoperative weight-bearing is restricted: an analysis of 4918 patients. Bone Joint J. 2018;100B(10):1377\u201384.","journal-title":"Bone Joint J"},{"issue":"7","key":"2872_CR109","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00590-019-02453-z","volume":"29","author":"J Warren","year":"2019","unstructured":"Warren J, Sundaram K, Anis H, McLaughlin J, Patterson B, Higuera CA, Piuzzi NS. The association between weight-bearing status and early complications in hip fractures. Eur J Orthop Surg Traumatol. 2019;29(7):1419\u201327.","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"2872_CR110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.physio.2020.04.009","volume":"108","author":"M Beckmann","year":"2020","unstructured":"Beckmann M, Bruun-Olsen V, Pripp AH, Bergland A, Smith T, Heiberg KE. Effect of exercise interventions in the early phase to improve physical function after hip fracture - A systematic review and meta-analysis. Physiotherapy. 2020;108:90\u20137.","journal-title":"Physiotherapy"},{"issue":"10","key":"2872_CR111","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s11606-020-05666-9","volume":"35","author":"C Sherrington","year":"2020","unstructured":"Sherrington C, Fairhall N, Kirkham C, Clemson L, Tiedemann A, Vogler C, Close JCT, O\u2019Rourke S, Moseley AM, Cameron ID, Mak JCS, Lord SR. Exercise to reduce mobility disability and prevent falls after fall-related leg or pelvic fracture: RESTORE randomized controlled trial. J Gen Intern Med. 2020;35(10):2907\u201316.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"2872_CR112","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.autrev.2013.02.004","volume":"12","author":"P Pludowski","year":"2013","unstructured":"Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, Shoenfeld Y, Lerchbaum E, Llewellyn DJ, Kienreich K, Soni M. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 2013;12(10):976\u201389.","journal-title":"Autoimmun Rev"},{"issue":"21","key":"2872_CR113","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042\u201357.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s12094-022-02905-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02872-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:56:22Z","timestamp":1664481382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02872-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":113,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02872-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12094-022-02905-9","asserted-by":"object"}]},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-022-02905-9","URL":"https:\/\/doi.org\/10.1007\/s12094-022-02905-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Santos Casta\u00f1eda has received personal fees from Amgen, Gebro Pharma, Gedeon-Richter Spain, Gr\u00fcnenthal, Lilly, MSD, Pfizer, Roche, Sanofi, Stada, SOBI and UCB, and he is assistant professor of the UAM-Roche EPID-Future chair, Universidad Aut\u00f3noma de Madrid (UAM), Madrid, Spain. Ana Casas has received consultant or speaker\u2019s fees from Novartis, Roche, Astra Zeneca and Pierre Fabre. Ar\u00e1nzazu Gonz\u00e1lez-del-Alba has received research funding from Astellas, travel grants from Astellas, Jansen, Sanofi, BMS, Roche, Pfizer, MSD and Ipsen and honoraria for speaking engagements, membership of advisory boards and continuing medical education from Janssen, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Eusa Pharma, Eisai and Astra Zeneca. Guillermo Mart\u00ednez-D\u00edaz-Guerra has received research funding from Lilly and Amgen; travel grants from Lilly, UCB, and Amgen; speaker\u2019s fees from Lilly, Amgen, Kyowa Kirin, Italf\u00e1rmaco, and Gebro Pharma; and honoraria for membership of advisory boards and continuing medical education from Lilly, UCB, Amgen, Kyowa Kirin, Takeda, and Alexion. Xavier Nogu\u00e9s has received consultant or speaker\u2019s fees from Amgen, Lilly, Faes Farma and UCB Pharma. Cristina Ojeda Thies has recieved honoraria for presentations and continuing medical education from AMGEN, UCB Pharma, Gr\u00fcnenthal and MBA Surgical Empowerment. \u00d3scar Torregrosa Suau declares no conflicts of interest. \u00c1lvaro Rodr\u00edguez-Lescure has received consultant or advisor fees from Roche, Pfizer, Novartis, Lilly, MSD, AstraZeneca, and Daiichi-Sankyo, and research funding\u00a0for his institution from Roche, Novartis, Pfizer, Lilly, AstraZeneca, Amgen, MSD, BMS, Zymeworks, and GEICAM; he has also received speaker\u2019s fees from Roche, Pfizer, Novartis, Lilly, AstraZeneca, MSD, Merck, Pierre-Fabr\u00e9, and Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}